Wedbush Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Underperform

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) was downgraded by Wedbush from a “neutral” rating to an “underperform” rating in a research report issued on Tuesday, Briefing.com reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $15.00. Wedbush’s price objective would indicate a potential downside of 33.33% from the company’s current price.

A number of other equities analysts have also weighed in on ZNTL. HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Stifel Nicolaus reduced their target price on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Finally, Wells Fargo & Company cut Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $29.83.

Read Our Latest Report on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Trading Down 28.5 %

NASDAQ ZNTL traded down $2.39 during trading on Tuesday, hitting $6.00. The company had a trading volume of 7,938,402 shares, compared to its average volume of 811,351. Zentalis Pharmaceuticals has a one year low of $5.91 and a one year high of $30.53. The company’s fifty day moving average is $11.77 and its 200-day moving average is $13.13. The company has a market cap of $426.18 million, a price-to-earnings ratio of -1.80 and a beta of 1.83.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the prior year, the firm earned ($1.07) EPS. As a group, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.72 EPS for the current year.

Insider Activity at Zentalis Pharmaceuticals

In other news, insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the sale, the insider now owns 373,876 shares in the company, valued at $4,718,315.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Diana Hausman sold 3,356 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the sale, the insider now owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Cam Gallagher sold 9,597 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $38,000. Tower Research Capital LLC TRC lifted its position in shares of Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after purchasing an additional 2,589 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after purchasing an additional 1,519 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after purchasing an additional 6,379 shares during the last quarter. Finally, OneAscent Financial Services LLC bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $156,000.

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Recommended Stories

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.